Printer Friendly

Radioactive antibodies: selective targeting and treatment of cancer and other diseases.

For several decades, radioactive antibodies have been used as imaging and therapeutic agents, but recent developments raise enthusiasm that diverse imaging agents for various diseases as well as a new generation of cancer therapeutics are more likely than ever before to be used in the near future.

Representative cases

Case 1

A 16-year-old boy came to the emergency room with abdominal pain, nausea, and vomiting. His doctors decided to use an investigational agent consisting of an antibody fragment that binds to activated neutrophils, a form of white blood cells accumulating in sites of infection, and is labeled with technetium-99m ([sup.99m]Tc), an isotope that is routinely used for nuclear scans that are used as diagnostic imaging studies. An hour after injecting this radioactive antibody, a nuclear scan showed a focus of radioactivity in the right lower abdomen, in the region of the appendix, which suggested that there was a focus of infection (Figure 1) because of an accumulation of neutrophils. He then went to surgery, where an inflamed appendix (7.5 cm in length and 1.5 cm in diameter) was removed. (1)

Case 2

A 26-year-old woman with aquired immunodeficiency disease (AIDS) was suffering from progressive breathing difficulty, congestion, cough, and other symptoms of pneumonia, which was confirmed by chest X-ray. An experimental antibody against Pneumocystis carinii was labeled with [sup.99m]Tc and injected into the patient. Twenty-four hours later, her body was scanned with a nuclear camera, which showed accumulation of radioactivity in the right lower lung lobe and in the left lung (arrows), coinciding with the pneumonia seen on the chest X-ray (Figure 2). A bronchial fluid aspirate revealed Pneumocystis organisms, which can infect immunocompromised patients. (2)

Case 3

A 67-year-old woman was in relapse with a non-Hodgkin's lymphoma (NHL) after receiving 3 cycles of chemotherapy, irradiation to her abdomen, and 2 immunotherapy treatments with an anti-CD20 antibody. Tumors were found in the abdomen by axial computed tomography (CT) and by positron-emission tomography (PET) scans using fluorine-18 deoxyglucose ([sup.18]FDG), as shown in Figure 3. Epratuzumab, a humanized antibody against a surface marker of NHL (CD22), was labeled with a beta-emitting radionuclide, yttrium-90 ([sup.90]Y) and given in weekly fractionated doses over 3 weeks. Three months later, scans showed that all disease had disappeared, but by 6-month follow-up there was recurrence at the same sites in the abdomen. A second treatment course of 3 weekly injections was given, and, again, all disease responded well at the 6-week evaluation. Based on the results of PET scans, the patient enjoyed a complete disappearance of disease for 32 weeks, without experiencing the side effects usually encountered with cytotoxic drugs. (3)

These cases are a few examples of how radioactive antibodies are being studied and introduced into medical practice, as more specific diagnostic or therapeutic agents. This article discusses this new technology and its development, current uses, and future prospects.

Antibodies are used to target and image disease

At the beginning of the 20th century, German chemotherapist Paul Ehrlich coined the term Zauberkugeln (or magic bullets) to elucidate the idea of using the body's immune system to selectively target receptors on microbes. (4) As early as the 1950s, scientists such as David Pressman, PhD (Sloan-Kettering Cancer Center, New York, NY, and then Roswell Park Cancer Institute, Buffalo, NY) and William Bale, PhD, and Irving Spar, PhD (University of Rochester, NY) investigated this idea of selective tumor localization by making antibodies against receptors on rodent tumors. (5,6) They radiolabeled these antibodies with iodine-131 ([sup.131]I) and were then able to show selective tumor targeting by measuring the higher radioactivity in the tumor (using a radiation counter) and comparing the measurements with those of normal tissues. Antibodies are glycoproteins produced by lymphocytes to combat infection and foreign organisms with a system that has evolved over millions of years to protect animals from their environment. As part of the immune regulatory system, antibodies are also used as vaccines for treating or preventing infections and are being developed for use against other diseases, including cancers. They are depicted as Y-shaped molecules, where the 2 arms of the Y are the binding sites to receptors, or specific "antigens" that evoke these antibodies and permit them to attach to the same antigens when present in the body (Figure 4). The tail of the antibody recruits immune cells and factors, such as lymphocytes and complement, which join forces with these circulating antibodies to overcome infection or expel foreign invaders. Until the early 1980s, studies using radiolabeled antibodies were confined to the use of radioiodine (eg, 131I and 125I), but this field has greatly benefited from the contributions of many chemists, such as Donald Hnatowich, PhD (University of Massachusetts, Worcester), Claude Meares, PhD (University of California at Davis), and Otto Gansow, PhD and Martin Brechbiel, PhD (National Institutes of Health, Bethesda, MD), who developed chelates, or metal-binding chemicals, that could be coupled to antibodies, which greatly expanded the number and types of radionuclides that could be attached to antibodies for detection or therapy, such as indium-111 ([sup.111]In) and [sup.90]Y. (7-10)





Once it was shown that antibodies produced in animals (so-called polyclonal antibodies) could distinguish tumors growing in rats from their normal tissues, the challenge was to translate this to use in cancer patients. Before embarking on clinical studies, it was necessary to first reproduce these findings in an animal model growing human cancer transplants, using antibodies against a human tumor antigen that could be localized in these tumors. At that time, none of the immunodeficient mouse models that are currently available for use by researchers were available. In 1972, we were fortunate to have observed that a human intestinal tumor growing in the cheek pouches of hamsters expressed carcinoembryonic antigen (CEA). (11) Carcinoembryonic antigen was first described in 1965 by Phil Gold, MD, PhD, and Sam Freedman, DSc, MD, at McGill University in Montreal, as an intestinal-specific human cancer antigen. (12) We reasoned that this would be a selective target for delivering radioactivity to intestinal tumors when antibodies against CEA were tagged with radionuclides. In 1973, with F. James Primus, PhD (Hoffman-LaRoche, Nutley, NJ and University of Kentucky, Lexington, KY) and Hans J. Hansen, PhD (Hoffman-LaRoche), we showed, for the first time, that human tumors grown in hamsters could, in fact, localize radioactive antibodies. (13,14) This set the stage for clinical studies and--after developing and purifying clinical-grade antibodies to CEA, and labeling them with [sup.131]I (an isotope commonly used in humans to detect and treat thyroid tumors that selectively absorb iodine)--we embarked to prove that cancers in patients could be detected and actually localized with radioactive antibodies. At this time, one concern was that CEA, which also circulates in the blood of these cancer patients, would bind the injected antibodies and prevent it from reaching the tumors. We disproved this dogma when, in the first patients reported with this new technology in 1978, we visualized CEA-producing tumors and failed where there were tumors devoid of CEA. (15) Equally important was the observation that cancers other than intestinal tumors (including breast, uterine, and lung tumors) also produced sufficient CEA to be revealed by these radioactive antibodies. This observation gave birth to the use of radioactive antibodies for disease detection, which the authors termed radioimmunodetection (Figure 5), or for therapy (termed radioimmunotherapy). (16)



In the ensuing years, more refined monoclonal antibodies that could be mass-produced evolved, isotopes other than [sup.131]I were attached to antibodies, and antibody forms were changed to make them smaller and more compatible for use in humans. (17,18) Once this principle for locating and visualizing CEA-expressing cancers was proven, radioimmunodetection was applied to other cancers and diseases, even targeting antigens expressed in clots, heart infarcts, and infections. In fact, we and others showed that small antibody fragments against a receptor on activated white blood cells (neutrophils) would accumulate at sites of infection and could be tagged with a common imaging isotope, [sup.99m]Tc. This could then reveal sites of infection (such as bone infection), osteomyelitis (Figure 6), or appendicitis (Figure 1), thus providing rapid and more selective diagnostic information. (1,19-21)


We also showed that immunocompromised patients with a rare infection, Pneumocystis carinii pneumonia, could have their infection visualized with radioactive antibodies developed by our colleague Peter Walzer, MD (University of Cincinnati, OH) against this organism (Figure 2). (2) More recently, Arturo Casadevall, MD, PhD, and Ekaterina Dadachova, PhD, at the Albert Einstein College of Medicine (Bronx, NY) have shown that they could localize and treat fungal infections in mice, such as Crytopoccus and Histoplasma, with radioactive antibodies, thus anticipating a new method of treating serious and resistant infections. (22,23) Several antibody-based imaging products have been commercialized, based on either intact murine immunoglobulin or Fab' fragments, which are much smaller and, therefore, less immunogenic and more rapid targeting agents. (24,25) Nevertheless, the adoption of these nuclear imaging methods was slow, since the low contrast of the images required considerable experience by the nuclear physician, and other imaging agents, although less disease-specific, were being introduced.

New classes of imaging agents

Antibodies, and smaller fragments thereof, have been developed against many different antigens associated with disease in order to specifically image these diseases. (25,26) These have included antibodies for imaging colorectal cancer (eg, satumomab pendetide, (27) arcitumomab (24)), prostate cancer (eg, capromab pendetide (28-30)) NHL, (31) liver cancer, (32) myocardial infarcts (imciromab penlefate (33-35)), infection and inflammation (eg, sulesomab, fanolesomab (36-38)), specific infections, (2) and clots, (39) to mention a few that are now available or in development. Either the intact immunoglobulin, its Fab' fragment, or even smaller antigen-binding Fv units can be used when radiolabeled. The most popular imaging isotopes are [sup.99m]Tc and [sup.111]In, although recent intensive research has included [sup.124]I (iodine-124), [sup.68]Ga (gallium-68), [sup.64]Cu (copper-64), and [sup.18]F (fluorine-18) as PET agents for development of ImmunoPET, which provides the specificity of antibodies and the sensitivity, or improved image resolution, of PET isotopes. (40) Steven M. Larson, MD, Chief of Nuclear Medicine at the Memorial Sloan-Kettering Cancer Center (New York, NY) was one of the first to show the targeting of tumors with antibodies labeled with the positron emitter [sup.124]I. (41)

With the data showing that radioactive antibodies could selectively target and image diseases that express the specific antigens, we and other researchers focused on applying this technology to radioimmunotherapy (RAIT) of cancer.

Radioimmunotherapy of cancer

Cancer treatment is dominated by 3 therapeutic procedures--surgery, radiation, and chemotherapy. If cancer is detected early, when it is localized, surgery and/or radiation therapy could be adequate to control or eradicate disease. Radiation therapy typically involves focusing an external beam of radiation to the specific area of the body that has the tumor mass (Figure 7). Alternatively, radioactive "seeds," which will emit local radiation within the region, can be implanted into the tumor area (brachytherapy). Unfortunately, cancer is frequently detected after it has spread beyond the original tumor site to other tissues and organs (metastasis), so that a systemic therapy is then required. Chemotherapy is the primary option for systemic therapy, although antibodies have recently been introduced as another treatment modality (immunotherapy), especially used in combination with anticancer drugs. The same kind of antibodies, however, can be used to carry radioactivity throughout the body and to deliver toxic radiation more selectively to cancer cells (Figure 7).

Although considerable research was undertaken in solid cancers (such as intestinal, breast, ovarian, and other carcinomas), the first true evidence of success came from the use of radiolabeled antibodies against marker antigens of hematologic cancers, such as NHL, a cancer of the lymphatic system. In the past 30 years, the U.S. incidence of NHL has increased significantly, becoming the fifth most common and sixth most fatal cancer in the United States, with approximately 270,000 Americans currently affected. An estimated 60,000 new U.S. cases of NHL will be diagnosed this year, and only approximately half of these cases will be cured. Normal and malignant lymphocytes express various receptors that are targeted by monoclonal antibodies, which are sometimes referred to as cluster designation (CD) types (eg, CD19, CD20, CD22; Figure 8), as well as human leukocyte transplantation antigen, HLA-DR.


Gerald DeNardo, MD, and Sally DeNardo, MD, at the University of California at Davis, were among the first to show successful therapy of NHL with radioactive antibodies against HLA-DR. (41) Oliver Press, MD, PhD, at the Fred Hutchinson Cancer Research Center (Seattle, WA) pioneered the use of very high doses of radioiodinated anti-CD20 antibodies under protection of bone marrow transplantation (to overcome the radiation toxicity to the bone marrow) for very effective NHL treatment. He and his collegues have even shown the feasibility and advantage of combining RAIT with chemotherapy. (42-48) Indeed, targeting NHL with murine antibodies against CD19 and CD20 (not conjugated with isotopes) was the subject of clinical studies for more than 20 years, but the development of a human/mouse chimeric antibody against CD20, called rituximab, revolutionized the therapy of NHL and spurred further developments in monoclonal antibodies for other cancers. (49) Rituximab induces remissions in roughly half of patients with the indolent form of NHL, and, although it is not curative by itself, it can improve the effects of standard chemotherapy and increase the number of cases of complete disappearance of tumor in many NHL types. Particularly intriguing is its relative lack of major toxicities, in contrast to standard anticancer drugs that often cause suppression of blood cells, mouth ulcers, and hair loss.


Thomas Witzig, MD, and Gregory Wiseman, MD (Mayo Clinic, Rochester, MN), Susan Knox, MD, PhD (Stanford University, Stanford, CA), and Christine White, MD (IDEC Pharmaceutical, Biogen Idec, Inc., Cambridge, MA) were instrumental in the clinical investigation that showed the superiority of a radiolabeled antibody treatment compared with the unlabeled antibody, which led the U.S. Food and Drug Administration (FDA) to approve the first radioimmunotherapeutic agent for cancer ([sup.90]Y-ibritumomab tiuxetan).50,51 A combination of rituximab with a therapeutic radiometal, [sup.90]Y-ibritumomab tiuxetan is [sup.90]Y attached to the mouse antibody that was commercialized in 2002 and is used to treat the indolent form of NHL. (52)

A second radioimmunotherapeutic against CD20, [sup.131]I-tositumomab, for the treatment of NHL, was also approved for U.S. use in 2003, and it involves a different radioisotope, iodine-131 ([sup.131]I). (53,54) Although this is a mouse antibody (which has a different form of radioactivity), both radiolabeled products appear to have similar efficacy results, which clearly show a significant improvement in shrinking tumors as compared with their nonradioactive forms. (50,55) While clinical data showing that these treatments significantly increase survival are lacking, highly durable, complete responses have been reported. (56-58) Although their applications to date have been restricted to patients who have failed to respond to other forms of therapy, results reported by Mark S. Kaminski, MD, and Richard Wahl, MD, of the University of Michigan showed impressive responses as a first treatment in patients with the indolent form of NHL. (54) One concern raised in the use of these types of treatment has been the possibility of future development of myelodysplastic syndrome/acute myeloid leukemia. (52) While a low incidence was reported in patients previously treated with chemotherapy before receiving a radiolabeled antibody, an evaluation has shown that none of the 76 patients given [sup.131]I-tositumomab as a first-line treatment has developed these conditions during a 5-year follow-up. (59) In addition, studies have shown that patients are able to receive subsequent chemotherapy or a second radioantibody treatment successfully after receiving radioimmunotherapy, which further supports integrating these treatments into a standard therapeutic regimen. (60,61)


In addition to targeting CD20, we are studying a humanized antibody (less mouse protein) against CD22, another marker for NHL, labeled with [sup.90]Y, as a fractionated, repeated therapy in indolent and aggressive forms of NHL (Figures 3 and 9). Patients who may become resistant to a CD20 antibody therapy could have this second therapeutic option. (62) In addition to the successful treatment of lymphoma, David A. Scheinberg, MD, PhD, and Joseph G. Jurcic, MD (Memorial Sloan-Kettering Cancer Center, NY, NY) have the lead in treating acute myeloid leukemia with radiolabeled antibodies. (63,64)

Numerous antibodies against solid tumors have been evaluated for therapeutic applications. (65) Although antibodies to CEA were among the first to be studied in a variety of cancers, Jeffrey Schlom, PhD, and David Colcher, PhD (National Cancer Institute, Bethesda, MD) developed the B72.3 against a tumor-associated glycoprotein and its subsequent second-generation monoclonal antibodies (CC49) and other molecularly engineered products that have been widely studied in colorectal, breast, and other cancers, not only for imaging and therapy, (66-69) but also for use with an intraoperative probe. (70) In contrast to the experience in NHL and other tumors of the blood system, radiolabeled antibodies have been less effective when used to treat solid tumors, such as colorectal, breast, lung, ovarian, and other carcinomas. (65) The same radiation dose that shrinks lymphoma is less effective in these other cancers, so it is concluded that lymphomas are more sensitive to radiation, but the basis for this radiosensitivity is poorly understood. Such factors as increased vascularization, less fibrous connective tissue, and higher number of tumor cells more diffusely spread in lymphomas are just some of the reasons speculated for their responding so well. It could also be that the direct effects of radiation are supplemented by antitumor effects of the antibodies themselves in these lymphomas, or that patients more readily invoke immune responses to lymphoma than they do to solid tumors. Further, the dose delivered by giving the highest tolerated amount of radioactivity attached to an antibody is less likely to show tumor shrinkage in larger tumors (eg, >5 cm) than in smaller ones, especially when there are small clusters of cancer cells. For example, giving RAIT to animals during an early phase of metastasis can affect survival significantly, even resulting in cures (Figure 10). (71) Initial clinical studies reported by Thomas M. Behr, MD, and Wolfgang Becker, MD (University of Gottingen, Germany) support this preclinical finding. (72) More recently, a clinical trial performed under the direction of Torsten Liersch, MD, with the other investigators from the University of Gottingen, reported that colorectal cancer patients having resection of their liver metastasis who received postoperative radioimmunotherapy with [sup.131]I-anti-CEA humanized antibodies did significantly better, with doubling survival time, than did a contemporaneous control group of patients who did not receive radioimmunotherapy. (73)

Also, improved methods for increasing the radiation dose delivered selectively to tumors need to be developed. One obvious approach is to deliver the radioactivity locally, such as in regional or intratumoral applications. Indeed, both of these options have shown encouraging results clinically, particularly when delivering the radiolabeled antibody into surgical reservoirs for treating malignant brain tumors, as has been described by Pietro Riva, MD, in Cesena, Italy, Giovanni Paganelli, MD, at the European Institute of Cancer in Milan, Italy, and by Darrell D. Bigner, MD, PhD, Henry S. Friedman, MD, and Michael R. Zalutsky, PhD, at Duke University (Durham, NC). Others, such as Ruby M. Meredith, MD, PhD, at the University of Alabama, in Birmingham, have examined the delivery of radioactive antibodies directly into the abdominal cavity. (74-80)

Table 1 summarizes many of the radiolabeled antibodies in clinical research, showing that radioimmunotherapy is being actively investigated in a wide variety of cancers using antibodies to different tumor-associated antigens. While there are currently only 2 therapeutic agents approved for human use, it is important to understand the complexity and diversity involved in these types of investigations. Selection of appropriate markers for specific targeting is a major challenge, while selecting the appropriate radionuclide, method for radiolabeling, and even the form of antibody used in the targeting procedure are all variables that need to be carefully considered for the particular clinical situation.

Table 2 is a partial listing of some of the radionuclides used for radioimmunotherapy and highlights just some of issues that investigators must consider while evaluating prospective radionuclides. Most are beta-emitters, and some of these travel several millimeters in tissues, a distance that extends the range where the radionuclide could potentially damage cells at a length equal to the diameter of as many as 50 to even 200 cells. Beta-emitters are generally preferred for killing visible tumors, but their long range can also cause collateral damage to adjacent normal tissues. Antibodies radiolabeled with beta-emitters that stay in the blood for several days will damage the blood-forming cells found in the bone marrow, which lowers blood counts in treated patients and limits the amount of radioactivity that can be given. Alpha-emitters, while they have a relatively short range (eg, up to 10 cell diameters), are much more potent cell-killers than beta-emitters. Because of their short range, alpha-emitters have most commonly been used to treat blood cancers, such as leukemia, because they frequently are found as single cells or small cell clusters. These cancers are readily accessible to the radiolabeled antibody injected in the bloodstream. This is important, since many of the alpha-emitters decay in a short period of time and, therefore, must be quick to selectively localize the tumor cells. Alpha-emitters are also being used to treat cancers regionally, such as ascites and peritoneal implants in ovarian cancer, and brain cancers. Low-energy electron emitters have an even smaller range than alpha-emitters and are capable of killing mostly single cells, which reduces damage to neighboring normal cells. However, a highly efficient means of delivering these types of radionuclides is required in order to increase the likelihood of specific cell killing. By targeting radionuclides with different path lengths, it may be possible to effectively kill visible, yet small, solid tumors, while following with a radionuclide of shorter path-length to seek out microscopic deposits of tumors that might not be as effectively killed by a targeted beta-emitter.

David A. Scheinberg, MD, PhD, at Memorial Sloan-Kettering Cancer Center and M. Jules Mattes, PhD, at the Garden State Cancer Center at the Center for Molecular Medicine and Immunology (Belleville, NJ), have found that very short-range and potent alpha-emitters and low-energy electrons can be used with antibodies to selectively kill small clusters of human cancer cells in animal models, thus expanding the choice of therapeutic radionuclides beyond the more conventional beta-emitters ([sup.131]I and [sup.90]Y) with longer path lengths. (63,81,82)


Restructuring antibodies by molecuar engineering

The art of antibody preparation has been revolutionized by molecular biology. The development of monoclonal antibodies from mouse cells by Georges Kohler, PhD, and Cesar Milstein, PhD (the University of Cambridge, England) can be credited as one of the most important developments in molecular immunology. In 1984, they shared the Nobel Prize for Physiology and Medicine just 9 years after publishing their seminal paper on hybridoma technology. (83) Just as polyclonal antibodies were quickly replaced when techniques for monoclonal antibody production were developed, murine monoclonal antibodies are being superseded with other molecular constructs that more closely mimic human antibodies. Initially limited to only 3 forms of antibodies (eg, intact IgG, F[(ab').sub.2], and Fab'), investigators now have an expanding repertoire of antibody forms with variable numbers of antigen-binding sites and with different molecular sizes and shapes. Even their binding affinity, immune effector activity, and the manner in which they are cleared from the blood can be modified. As their basis, many of these constructs use molecules known as single-chain variable fragments (scFv), which consist of the variable-light ([V.sub.L]) and variable-heavy ([V.sub.H]) chain regions of an antibody that contain the 3 complementarity-determining regions (CDRs) responsible for antigen binding. Brought together by the insertion of a variable-length amino acid linker, these 2 chains fold to form a 25,000 dalton (25 kD) molecular size molecule with 1 binding site (about one sixth the size of an intact, natural, IgG antibody with 2 binding arms. But, as the amino acid linker length is changed, these molecules can self-anneal to form diabodies, triabodies, and even tetrabodies (2, 3, and 4 binding sites, respectively). Still other forms, such as sc[(Fv).sub.2], [[sc[(Fv).sub.2]].sub.2], scFv-Fc, and mini-bodies, have been described (Figure 11).

Targeting studies with these new molecular antibody forms have suggested that some are preferable over others for either imaging or therapy. The smallest clear very rapidly from the blood, which improves tumor/blood ratios as compared with those observed with an intact radiolabeled IgG. However, the blood clearance of these molecules can be so fast that the tumor uptake is also correspondingly much lower than that achieved with the larger constructs. In addition, the selection of a particular form might also affect the choice of radionuclide used. Antibody versions that are smaller than ~60,000 are directly filtered from the blood into the kidneys. However, in contrast to conjugates with radiometals for which kidney uptake can be high, renal retention by radioiodinated constructs is reduced considerably. While the choice of an antibody form and a radionuclide may depend on the intended application, there have been several advances, primarily in preclinical testing, of improved targeting and therapy with several of these reengineered constructs, such as has been reported by Anna Wu, PhD, (84) from the University of California at Los Angeles, and Richard H. Begent, MD, (85) at the Royal Free Hospital and University College Medical School in London, England.

Toward new imaging and therapy methods: Pretargeting

An alternative to using directly radiolabeled antibodies is a procedure known as pretargeting, a multistep process by which the radionuclide is attached to a small compound that is cleared very rapidly (in minutes) from the blood. The antibody has dual specificity, with 1 arm binding to the target antigen and the other to a recognition unit on a small radiolabeled compound. David Goodwin, MD, of Stanford University and VA Hospital, Palo Alto, CA introduced this concept more than 15 years ago. (86,87) The 2 most common pretargeting procedures utilize a streptavidin-biotin recognition system (advanced by Donald Hnatowich, PhD, of the University of Massachusetts, Worcester; Giovanni Paganelli, MD, European Institute of Cancer, Milan, Italy; and NeoRx's John Reno, PhD, and Alan Fritzberg, PhD, Seattle WA), or a bispecific monoclonal antibody (bsMAb)-hapten model (Figure 12), as being pursued by our group and that of Otto Boerman, PhD, and Frans Corstens, MD, and their colleagues at the University Nijmegen (Netherlands) after the initial studies of Michael Delaage, PhD, and co-workers in Marseilles, France. (88-95) In our view, pretargeting methods utilizing bsMAb should have an advantage over those that involve streptavidin, since the immunogenicity of bsMAbs can be reduced or eliminated by the use of humanized bsMAbs, whereas host antibodies against streptavidin have occurred at high frequency. Bispecific antibodies also can be generated as small, antigen-binding variable domains (Fv) that improve the pharmacokinetic properties (localization and clearance) of the primary targeting agent, while also binding to a versatile, bivalent, peptide-hapten carrying an imaging or therapeutic radionuclide. (93-95)

This pretargeting strategy (Figure 12B) also appears to be promising for improved disease imaging, since it relies on the principle of reduced background radioactivity by allowing time for clearance of nontargeted bsMAb from the body before the peptide bearing a radioactive signal is given for disease localization. In the case of cancer, we are finding that human colonic cancer grown in immune-deficient mice can be visualized within 20 minutes of injecting the imaging signal (Figure 13) and that at 24 hours, ratios of uptake in tumor versus blood can exceed 100, which is 40-fold better then any directly labeled antibody or antibody fragment. (96) This pretargeting procedure, when used in combination with an [sup.124]I-labeled hapten-peptide for ImmunoPET imaging, provides a durable, strong signal in the tumor with much lower uptake in the normal tissues than [sup.18]FDG, thereby affording less ambiguous tumor targeting. (97) Recently, our group has shown the localization of a human colon cancer growing as discrete [less than or equal to]0.3-mm colonies in the lungs of nude mice with the same pretargeting ImmunoPET procedure (Figure 14). [sup.18]FDG was unable to disclose these very small lesions, which further illustrates how the enhanced sensitivity of this pretargeting procedure, along with its high specificity, could assist in the detection of cancer. Since antibodies exist for targeting various cancers, infections, myocardial damage, clots, emboli, and atherosclerotic plaques, a new generation of imaging and diagnostic agents for cancer and diverse diseases may now be developed using these antibodies combined with radioisotopes, along with the signal from various contrast agents for magnetic resonance imaging and ultrasonography. The challenge is to choose the most specific antibodies for creating bispecific constructs and to load the signal-generating contrast agent in sufficient quantity for image resolution with current cameras. The signal-bearing peptides can be devised to bear many end-groups as attachment sites and can be of virtually any size, so that such loads may be feasible, possibly also for drug delivery.


Pretargeting methods have also been shown to be more effective in selectively delivering radionuclides to tumors for therapy. (98-100) Using a bispecific antibody construct composed of an antibody fragment against CEA and another antibody fragment against a metallic compound that is bound to radioactive iodine ([sup.131]I), clinical trials that are being performed by us in France are showing excellent tumor imaging (Figure 15) and initial evidence that the radiation dose to the tumors, as compared with a directly radiolabeled antibody, can be improved. (101) Studies are in progress to assess whether these doses are sufficient to control tumor growth, but the advantage of using totally humanized, nonimmunogenic reagents is to permit repeated dosing, which is likely to be needed. Early results in patients with lung, colorectal, and medullary thyroid cancers that produce CEA indicate a slowing of tumor growth. For example, a retrospective analysis of medullary thyroid cancer patients treated with an anti-CEA bispecific antibody pretargeting procedure and an [sup.131]I-labeled hapten-peptide has revealed a subset of patients in whom a significant survival advantage occurs. (102) These encouraging findings suggest that more laboratory research should be conducted to determine the best reagents, appropropriate treatment regimens, and specific tumor types that may be the best candidates for this form of radioimmunotherapy.




We have found that having an antibody with 2 binding arms against the cancer antigen CEA and 1 binding arm against the peptide that carries the therapeutic isotope, [sup.90]Y, appears to be optimal. (103,104) In a study that compared the efficacy of a CEA antibody directly labeled with [sup.90]Y with the 2-step pretargeting involving [sup.90]Y attached to the peptide, a clear advantage of pretargeting was shown; 30% of the animals that had initially had well-developed tumors were cured, while none were cured in the control group receiving directly radiolabeled antibody. (98,99) This advantage was again confirmed in another model of human NHL growing in immunodeficient mice, where pretargeting involving antibodies against CD20 receptors on the tumor cells again showed better results in controlling tumor growth than did a directly radiolabeled antibody, which is similar to the two CD20 antibody products currently approved for NHL radioimmunotherapy. (104)

Bispecific antibody pretargeting-either for improved cancer imaging or therapy--is still in the early phase of development, despite already showing evidence of safety and efficacy in animal and human studies, because many questions still need to be resolved: What is the most effective form of the bispecific antibody construct? How high does it need to be dosed and how often? Which peptide and isotope are preferred? Are there any long-term toxicities when high and/or repeated therapeutic doses are given? Other important matters involve stability and production properties, if these are to become new candidates for commercial use. Since antibodies can be made against other markers of disease, as discussed above, what will be the most important disease targets for applying this new technology? Could this also be expanded to the more selective delivery of other agents, such as drugs, toxins, hormones, enzymes, vaccines, or even genes as a next generation for gene therapy or diagnostic imaging agents? We believe that these studies with radioactive antibodies have set the stage for asking such questions and for stimulating these other applications.


(1.) Passalaqua AM, Klein RL, Wegener WA, et al. Diagnosing suspected acute nonclassic appendicitis with sulesomab, a radiolabele d antigranulocyte antibody imaging agent. J Pediatr Surg. 2004; 39: 1338-1344.

(2.) Goldenberg DM, Sharkey RM, Udem S, et al. Immunoscintigraphy of Pneumocystis carinii pneumonia in AIDS patients. J Nucl Med. 1994;35:1028-1034.

(3.) Chatal JF, Harousseau JL, Griesinger F, et al. Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. J Clin Oncol (Meeting Abstracts). 2004;22:2545.

(4.) Himmelweit F. The Collected Papers of Paul Ehrlich. Vol 3. London, UK: Pergamon; 1960:59.

(5.) Pressman D; Korngold L. The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer. 1953;6:619-623.

(6.) Bale WF; Spar IR. Studies directed toward the use of antibodies as carriers of radioactivity for therapy. Adv Biol Med Phys. 1957;5:285-356.

(7.) Hnatowich DJ, Layne WW, Childs RL, et al. Radioactive labeling of antibody: A simple and efficient method. Science. 1983;220:613-615.

(8.) Scheinberg DA, Strand M, Gansow OA. Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Science. 1982; 215: 1511-1513.

(9.) Brechbiel MW, Gansow OA. Backbone-substituted DTPA ligands for 90Y radioimmunotherapy. Bioconjug Chem. 1991;2:187-194.

(10.) Moi MK, DeNardo SJ, Meares CF. Stable bifunctional chelates of metals used in radiotherapy. Cancer Res. 1990;50(3 suppl):789s-793s.

(11.) Goldenberg DM, Hansen HJ. Carcinoembryonic antigen present in human colonic neoplasms serially propagated in hamsters. Science. 1972;175: 1117-1118.

(12.) Gold P; Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med. 1965;122:467-481.

(13.) Primus FJ, Wang RH, Goldenberg DM, Hansen HJ. Localization of human GW-39 tumors in hamsters by radiolabeled heterospecific antibody to carcinoembryonic antigen. Cancer Res. 1973;33: 2977-2982.

(14.) Goldenberg DM, Preston DF, Primus FJ, Hansen HJ. Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G. Cancer Res. 1974;34(1):1-9.

(15.) Goldenberg DM, DeLand F, Kim E, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med. 1978; 298:1384-1386.

(16.) Goldenberg DM. Introduction to the International Conference on the Clinical Uses of Carcinoembryonic Antigen. Cancer. 1978;42(3 suppl):1397-1398.

(17.) Mach JP, Carrel S, Merenda C, et al. In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature. 1974;248:704-706.

(18.) Mach JP, Carrel S, Forni M, et al. Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: A critical evaluation. N Engl J Med. 1980;303:5-10.

(19.) Becker W, Bair J, Behr T, et al. Detection of soft-tissue infections and osteomyelitis using a technetium-99m-labeled anti-granulocyte monoclonal antibody fragment. J Nucl Med. 1994;35:1436-1443.

(20.) Becker W, Goldenberg DM, Wolf F. The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions. Semin Nucl Med. 1994; 24:142-153.

(21.) Becker W, Palestro CJ, Winship J, et al. Rapid imaging of infections with a monoclonal antibody fragment (LeukoScan). Clin Orthop Relat Res. 1996; (329):263-272.

(22.) Dadachova E, Nakouszi A, Bryan RA, Casadevall A. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci USA. 2003;100:10942-10947.

(23.) Dadachova E, Casadevall A. Treatment of infection with radiolabeled antibodies. Q J Nucl Med Mol Imaging. 2006;50:193-204.

(24.) Moffat FL Jr, Pinsky CM, Hammershaimb L, et al. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: Results of a pivotal, phase III trial. The Immunomedics Study Group. J Clin Oncol. 1996;14:2295-2305.

(25.) Goldenberg DM, Juweid M, Dunn RM, Sharkey RM. Cancer imaging with radiolabeled antibodies: New advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy. J Nucl Med Technol. 1997;25:18-23.

(26.) Goldenberg DM. Cancer imaging with CEA antibodies: Historical and current perspectives. Int J Biol Markers. 1992;7:183-188.

(27.) Abdel-Nabi H, Doerr RJ. Clinical applications of indium-111-labeled monoclonal antibody imaging in colorectal cancer patients. Semin Nucl Med. 1993; 23:99-113.

(28.) Lamb HM, Faulds D. Capromab pendetide. A review of its use as an imaging agent in prostate cancer. Drugs Aging. 1998;12:293-304.

(29.) Yao D, Trabulsi EJ, Kostakoglu L, et al. The utility of monoclonal antibodies in the imaging of prostate cancer. Semin Urol Oncol. 2002;20:211-218.

(30.) Goldenberg DM, DeLand FH. Clinical studies of prostatic cancer imaging with radiolabeled antibodies against prostatic acid phosphatase. Urol Clin North Am. 1984;11:277-281.

(31.) Murthy S, Sharkey RM, Goldenberg DM, et al. Lymphoma imaging with a new technetium-99m labeled antibody, LL2. Eur J Nucl Med. 1992;19:394-401. Comment in: Eur J Nucl Med. 1992;19:385-386.

(32.) Dresel S, Kirsch CM, Tatsch K, et al. Detection of hepatocellular carcinoma with a new alphafetoprotein antibody imaging kit. J Clin Oncol. 1997; 15:2683-2690.

(33.) Matsumori A, Yamada T, Tamaki N, et al. Persistent uptake of indium-111-antimyosin monoclonal antibody in patients with myocardial infarction. Am Heart J. 1990;120:1026-1030.

(34.) Khaw BA, Haber E. Imaging necrotic myocardium: Detection with 99mTc-pyrophosphate and radiolabeled antimyosin. Cardiol Clin. 1989;7: 577-588.

(35.) Khaw BA, Narula J. Antibody imaging in the evaluation of cardiovascular diseases. J Nucl Cardiol. 1994;1(5 Pt 1):457-476. Erratum in: J Nucl Cardiol. 1994;1:585.

(36.) Boerman OC, Rennen H, Oyen WJ, Corstens FH. Radiopharmaceuticals to image infection and inflammation. Semin Nucl Med. 2001;31:286-295.

(37.) Love C, Palestro CJ. Radionuclide imaging of infection. J Nucl Med Technol. 2004;32(2):47-57.

(38.) Gratz S, Schipper ML, Dorner J, et al. LeukoScan for imaging infection in different clinical settings: A retrospective evaluation and extended review of the literature. Clin Nucl Med. 2003;28: 267-276.

(39.) Cerqueira MD. Current status of radionuclide tracer imaging of thrombi and atheroma. Semin Nucl Med. 1999;29:339-351.

(40.) Kenanova V, Wu AM. Tailoring antibodies for radionuclide delivery. Exp Opin Drug Deliv. 2006; 3(1):53-70.

(41.) DeNardo SJ, DeNardo GL, O'Grady LF, et al. Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. Int J Cancer Suppl. 1988; 3:96-101.

(42.) Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1(anti-CD37) antibody. J Clin Oncol. 1989;7:1027-1038.

(43.) Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336-340.

(44.) Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94:1237-1247.

(45.) Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934-2942. Comment in: Blood. 2001; 98:1275-1276.

(46.) Press OW, Leonard JP, Coiffier B, et al. Immunotherapy of non-Hodgkin's lymphomas. Hematology Am Soc Hematol Educ Program. 2001; 221-240.

(47.) Gopal AK, Pagel JM, Rajendran JG, et al. Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. Biol Blood Marrow Transplant. 2006; 12:697-702.

(48.) Press OW, Unger JM, Braziel RM, et al for the Southwest Oncology Group. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24:4143-4149.

(49.) Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26(5 suppl 14): 66-73.

(50.) Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002; 20:2453-2463.

(51.) Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996; 2:457-470.

(52.) Sharkey RM, Burton J, Goldenberg DM. Radioimmunotherapy of non-Hodgkin's lymphoma: A critical appraisal. Expert Rev Clin Immunol. 2005;1:47-62.

(53.) Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19:3918-3928.

(54.) Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449. Comment in: N Engl J Med. 2005;352:496-498.

(55.) Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res. 2004;10: 7792-7798.

(56.) Buchegger F, Antonescu C, Delaloye AB, et al. Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer. 2006;94: 1770-1776.

(57.) Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23: 7565-7573.

(58.) Wiseman GA, Witzig TE. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm. 2005;20:185-188.

(59.) Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005; 105:4576-4582.

(60.) Dosik AD, Coleman M, Kostakoglu L, et al. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer. 2006;106: 616-622.

(61.) Kaminski MS, Radford JA, Gregory SA, et al. Retreatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol. 2005;23:7985-7993.

(62.) Linden O, Hindorf C, Cavallin-Stahl E, et al. Dose-fractionated radioimmunotherapy in nonHodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res. 2005; 11:5215-5122.

(63.) Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233-1239.

(64.) Kotzerke J, Bunjes D, Scheinberg DA. Radio-immunoconjugates in acute leukemia treatment: The future is radiant. Bone Marrow Transplant. 2005; 36:1021-1026.

(65.) Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med. 2005;46(suppl 1):115s-127s.

(66.) Schlom J, Colcher D, Szpak CA, et al. A monoclonal antibody (B72.3) to adenocarcinoma of the colon and related tumors. Prog Clin Biol Res. 1989; 288:63-72.

(67.) Colcher D, Minelli MF, Roselli M, et al. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res. 1988;48:4597-4603.

(68.) Goel A, Colcher D, Baranowska-Kortylewicz J, et al. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: Improved biodistribution and potential for therapeutic application. Cancer Res. 2000;60: 6964-6971.

(69.) Pavlinkova G, Booth BJ, Batra SK, Colcher D. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. Clin Cancer Res. 1999;5:2613-2919.

(70.) Sickle-Santanello BJ, O'Dwyer PJ, Mojzisik C, et al. Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors. Dis Colon Rectum. 1987;30:761-764.

(71.) Blumenthal RD, Sharkey RM, Haywood L, et al. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies. Cancer Res. 1992; 52:6036-6044.

(72.) Behr TM, Liersch T, Greiner-Bechert L, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer. 2002;94 (4 suppl):1373-1381.

(73.) Liersch T, Meller J, Kulle B, et al. Phase-II trial of CEA radioimmunotherapy with 131I-labetuzumab post salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results. J Clin Oncol. 2005;23:6763-6770.

(74.) Riva P, Franceschi G, Riva N, et al. Role of nuclear medicine in the treatment of malignant gliomas: The locoregional radioimmunotherapy approach. Eur J Nucl Med. 2000;27:601-609.

(75.) Riva P, Marangolo M, Lazzari S, et al. Locoregional immunotherapy of human ovarian cancer: Preliminary results. Int J Rad Appl Instrum B. 1989; 16:659-666.

(76.) Grana C, Bartolomei M, Handkiewicz D, et al. Radioimmunotherapy in advanced ovarian cancer: Is there a role for pre-targeting with 90Y-biotin? Gynecol Oncol. 2004;93:691-698.

(77.) Grana C, Chinol M, Robertson C, et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: A pilot study. Br J Cancer. 2002;86:207-212.

(78.) Zalutsky MR. Current status of therapy of solid tumors: Brain tumor therapy. J Nucl Med. 2005;46 (suppl 1):151s-156s.

(79.) Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002; 20:1389-1397.

(80.) Meredith RF, Alvarez RD, Partridge EE, et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study. Cancer Biother Radiopharm. 2001;16:305-315.

(81.) Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {alpha}-particle therapy. J Nucl Med. 2005. 46(suppl 1):199s-204s.

(82.) Mattes MJ. Radionuclide-antibody conjugates for single-cell cytotoxicity. Cancer. 2002;94(4 suppl): 1215-1223.

(83.) Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-497.

(84.) Wu AM. Engineering multivalent antibody fragments for in vivo targeting. Methods Mol Biol. 2004; 248:209-225.

(85.) Chester KA, Bhatia J, Boxer G, et al. Clinical applications of phage-derived sFvs and sFv fusion proteins. Dis Markers. 2000;16(1-2):53-62.

(86.) Reardan DT, Meares CF, Goodwin DA, et al. Antibodies against metal chelates. Nature. 1985; 316:265-268.

(87.) Goodwin DA, Meares CF, McCall MJ, et al. Pretargeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med. 1988;29:226-234.

(88.) Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987;28:1294-1302.

(89.) Paganelli G, Magnani P, Fazio F. Pretargeting of carcinomas with the avidin-biotin system. Int J Biol Markers. 1993;8:155-159.

(90.) Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA. 2000;97:1802-1807.

(91.) Le Doussal JM, Martin M, Gautherot E, et al. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: Enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med. 1989;30:1358-1366.

(92.) Boerman OC, Kranenborg MH, Oosterwijk E, et al. Pretargeting of renal cell carcinoma: Improved tumor targeting with a bivalent chelate. Cancer Res. 1999;59:4400-4405.

(93.) Chang CH, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther. 2002; 1:553-563.

(94.) Rossi EA, Chang C-H, Losman MJ, et al. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin Cancer Res. 2005; 11(19 Pt 2):7122S-7129S.

(95.) Rossi EA, Goldenberg DM, Cardillo TM, et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA. 2006;103: 6841-6846.

(96.) Sharkey RM, Cardillo TM, Rossi EA, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nature Med. 2005; 11:1250-1255.

(97.) McBride WJ, Zanzonico P, Sharkey RM, et al. Bispecific antibody pretargeting PET (ImmunoPET) with an 124I-labeled hapten-peptide. J Nucl Med. 2006;47: 1678-1688.

(98.) Sharkey RM, Karacay H, Cardillo TM, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res. 2005;11(19 Pt 2):7109s-7121s.

(99.) Karacay H, Brard PY, Sharkey RM, et al. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res. 2005;11: 7879-7885.

(100.) Goldenberg DM, Sharkey RM, Paganelli G, et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823-834.

(101.) Kraeber-Bodere F, Rousseau C, Bodet-Milin C, et al. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med. 2006;47:247-255.

(102.) Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryoni-cantigen radioimmunotherapy: A collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:1705-1711.

(103.) Karacay H, Sharkey RM, McBride WJ, et al. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: Role of the bispecific antibody's valency for the tumor target antigen. Bioconjug Chem. 2002;13:1054-1070.

(104.) Sharkey RM, Karacay H, Chang CH, et al. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia. 2005; 19:1064-1069.


Antibody: A serum protein that is formed in response to an antigen and reacts specifically with that antigen. All antibodies are members of a special class of serum proteins called immunoglobulins.

Antigen: A compound that is capable of stimulating the formation of and reacting with an antibody.

Hapten: Small-molecular-weight compounds that react with antibodies, but are not themselves immunogenic (ie, if injected in animals, they will not elicit an antibody response).

Epitope: A unique shape or a marker on the surface of an antigen that triggers an antibody response.

IgG: Immunoglobulin G, a specific class of immunoglobulin with a molecular weight of ~150,000 molecular size that has 2 antigen-binding arms.

Fab': An antibody fragment with one antigen-binding arm formed by the enzymatic digestion of an IgG with pepsin.

Monoclonal antibody: A highly specific, purified antibody that is derived from only 1 clone of cells and recognizes only 1 antigen.

Polyclonal antibody: Mixtures of antibodies, each capable of reacting with a different epitope on a given antigen or with different antigens.

Radioimmunodetection: The process of using antibodies labeled with a suitable radionuclide administered to patients to detect targeted disease sites. An imaging camera is used to identify the sites that bind the radioactivity.

Radioimmunotherapy: The process of adminstering antibodies bound with therapeutic radionuclides to patients so that the antibodies will bind to tumor cells that are destroyed by the radiation.

Radioisotope, radionuclide: An unstable isotope of an element that decays or disintegrates spontaneously, emitting radiation. Isotopes are atoms of the same element that have the same number of protons (and, hence, the same chemical properties) but a different number of neutrons (and therefore, different atomic weights).

Dr. Goldenberg is an Experimental Pathologist, Immunologist, and Clinical Investigator, and he is President, Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Belleville, NJ. Dr. Sharkey is a Tumor Biologist and Immunologist, Garden State Cancer Center, Belleville, NJ. Dr. Barbet is a Researcher in the use of antibodies in diagnosis and therapy, Cancer Research Department of Inserm, Nantes, France. Dr. Chatal is a Professor of Nuclear Medicine, and he directs the Nuclear Medicine Departments at the Rene Gauducheau Cancer Center and the University Hospital, Nantes, France.

David M. Goldenberg, ScD, MD; Robert M. Sharkey, PhD; Jacques Barbet, PhD; Jean-Francois Chatal, MD
Table 1. Radiolabeled antibodies for the treatment of cancer

Agent Indication

[sup.90]Y-ibritumomab tiuxetan * Non-Hodgkin's lymphoma
[sup.131]I-tositumomab * Non-Hodgkin's lymphoma
[sup.90]Y-epratuzumab anti-CD22 IgG Non-Hodgkin's lymphoma
[sup.213]Bi-HuM195 anti-CD33 IgG Leukemia
[sup.131]I-BC8 IgG Leukemia
[sup.90]Y-anti-Tac IgG T-cell lymphomas; non-Hodgkin's
 and Hodgkin's lymphomas
[sup.90]Y-Hu3S193 IgG Ovarian cancer
[sup.177]Lu-J591 IgG Prostate cancer
[sup.90]Y-PAM4 IgG Pancreatic cancer
[sup.131]I/[sup.90]Y -CC49-delta Colorectal cancer
[sup.125]I/[sup.131]I-A33 Colorectal cancer
[sup.90]Y-T84.66 anti-CEA IgG CEA-producing cancers
[sup.131]I-chTNT Lung cancer
[sup.131]I-Hepama-1 IgG Hepatocellular cancer
[sup.131]I-cG250 IgG Renal cancer
[sup.131]I-8H9 IgG CNS or leptomeningeal cancer
[sup.186]Re-bivatuzumab IgG Head and neck cancers
[sup.125]I-425 IgG Brain cancers (gliomas)
[sup.131]I-81C6 anti-tenascin; Gliomas
[sup.211]At-81C6; [sup.90]Y-BC-2
 and BC4

The Table provides a partial listing of different antibodies
radiolabeled with a variety of radionuclides that have been or are
actively being investigated for the treatment of cancer.

(* Approved by the U.S. Food and Drug Administration; all others are
under investigation.)

Table 2. Radionuclides for radioimmunotherapy

 Max (MeV) (90%)] (mm)
Radionuclide Half-life (hr) energy path length

 [sup.131]I 193 0.81 0.83
 [sup.90]Y 64 2.27 5.34
 [sup.177]Lu 161 0.50 0.60
 [sup.188]Re 17 2.12 4.42

 [sup.213]Bi 0.75 6.0
 [sup.211]At 7.2 6.0 ~0.05-0.08
 [sup.225]Ac 240 5.9

Low-energy electrons
 [sup.125]I 1440
 [sup.67]Ga 78 0.01-0.04 0.02-0.04
 [sup.111]In 67

A large number of radionuclides have been used in radioimmunotherapy.
This Table lists examples of different types used for different
applications. Beta-emitters are best used to kill tumors from a few
millimeters in diameter to several centimeters. Alpha- and low-energy
electron emitters are best used for small clusters of cells or even
individual cells.
COPYRIGHT 2007 Anderson Publishing Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Goldenberg, David M.; Sharkey, Robert M.; Barbet, Jacques; Chatal, Jean-Francois
Publication:Applied Radiology
Date:Apr 1, 2007
Previous Article:A program to decrease the need for pediatric sedation for CT and MRI.
Next Article:Radiological case of the month: Ugur Gonlugur, MD; Melih Kaptanoglu, MD; Tanseli Gonlugur, MD.

Related Articles
New technology will aid tumor treatment.
Patented method could overcome drug resistance in cancer.
Immunomedics obtains lymphoma antibody patent.
Lpath granted patent protection for anti-cancer anti-S1P antibody.
Arius announces new findings in Trop-2 and CD59 CANCER antibody programs - CD59 antibody uses novel approach to "de-cloak" cancers -.
The drug pipeline; Abbott striving for an edge in the race to develop new medicines.
Pre-targeting approach may lead to personalised cancer therapies.
Pre-targeting approach may lead to personalised cancer therapies.
New radioimmunotherapy offers promise to treat HIV infection, viral cancers.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters